Mikel Urroz

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, Alberto M. Borobia, Antonio J. Carcas et al. · The Lancet Infectious Diseases · 2021 · 102 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +13

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals

Ana Sofia Delgado, Stefan Stewart, Mikel Urroz et al. · Journal of Clinical Medicine · 2021 · 31 citations · Full text

Medicine, Pharmacology, Toxicology +17

Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data

Elena Ramı́rez, Mikel Urroz, María Amelia Fernández Rodríguez et al. · Frontiers in Pharmacology · 2020 · 27 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17